Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
Maurie Markman, MD, president of medicine and science at the Cancer Treatment Centers of America, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
For example, Markman says that the development of platinum-based chemotherapies such as paclitaxel started in ovarian cancer. Over time, this development became increasingly important in other cancers and tumor types as well.
Five years ago, treatments from ovarian cancer were not being used in areas such as lung cancer, but currently, these effective chemotherapies, targeted therapies, and immunotherapies are being used in a number of cancer types for chronic management, Markman adds.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More